- $79.66m
- $62.32m
- $213.40m
- 99
- 67
- 86
- 97
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 9.12 | ||
| PEG Ratio (f) | 0.38 | ||
| EPS Growth (f) | 31.55% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.92 | ||
| Price to Tang. Book | 2.96 | ||
| Price to Free Cashflow | 7.55 | ||
| Price to Sales | 0.38 | ||
| EV to EBITDA | 8.49 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.3% | ||
| Return on Equity | 10% | ||
| Operating Margin | 1.75% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 225.96 | 232.91 | 220.18 | 206.36 | 213.4 | 209.3 | 220.37 | 0.98% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -2.42 | +59.48 | +14.21 | -61.15 | -42.41 | +196.85 | +16.67 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
LifeVantage Corporation is engaged in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. The Company's dietary supplements include its flagship Protandim family of products, LifeVantage Omega+, ProBio, IC Bright, and Daily Wellness dietary supplements. The Protandim product line includes Protandim NRF1 Synergizer, Protandim Nrf2 Synergizer, and Protandim NAD Synergizer. TrueScience is its line of skin, hair, bath and body, and targeted relief products. The Company also markets and sells Petandim, its companion pet supplement formulated to combat oxidative stress in dogs; Axio, its nootropic energy drink mixes, and PhysIQ, its smartweight management system, which includes PhysIQ Fat Burn and PhysIQ Prebiotic, all formulated to aid in weight management.
Directors
- Garry Mauro NEC (73)
- Steven Fife PRE (62)
- Carl Aure CFO
- Matthew Cooley COO (48)
- Justin Rose CMO (53)
- Alissa Neufeld GCN (42)
- Michael Beindorff IND (69)
- Erin Brockovich IND (61)
- Raymond Greer IND (58)
- Darwin Lewis IND (62)
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 9th, 2018
- Public Since
- September 12th, 2012
- No. of Shareholders
- 90
- No. of Employees
- 248
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 12,868,462
- Address
- 3300 TRIUMPH BLVD, SUITE 700, LEHI, 84043
- Web
- https://www.lifevantage.com/
- Phone
- +1 8014329000
- Auditors
- Deloitte & Touche LLP
Upcoming Events for LFVN
Q4 2024 LifeVantage Corp Earnings Release
Similar to LFVN
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Aadi Bioscience
NASDAQ Capital Market
Acasti Pharma
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Aptorum
NASDAQ Capital Market
FAQ
What is the Lifevantage share price?
As of Today at 19:13 UTC, shares in Lifevantage are trading at $6.19. This share price information is delayed by 15 minutes.
How has the Lifevantage share price performed this year?
Shares in Lifevantage last closed at $6.19 and the price had moved by +90.69% over the past 365 days. In terms of relative price strength the Lifevantage share price has outperformed the S&P500 Index by +54% over the past year.
What are the analyst and broker recommendations for Lifevantage?
The overall consensus recommendation for Lifevantage is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Lifevantage dividend yield?
The Lifevantage dividend yield is 2.18% based on the trailing twelve month period.
Does Lifevantage pay a dividend?
Last year, Lifevantage paid a total dividend of $0.14, and it currently has a trailing dividend yield of 2.18%. We do not have any data on when Lifevantage is to next pay dividends.
When does Lifevantage next pay dividends?
We do not have data on when Lifevantage is to next pay dividends. The historic dividend yield on Lifevantage shares is currently 2.18%.
How do I buy Lifevantage shares?
To buy shares in Lifevantage you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Lifevantage?
As of the previous close price of $6.19, shares in Lifevantage had a market capitalisation of $79.66m.
Where are Lifevantage shares listed?
Here are the trading details for Lifevantage:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: LFVN
What kind of share is Lifevantage?
Based on an overall assessment of its quality, value and momentum Lifevantage is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Lifevantage share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Lifevantage share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lifevantage. Over the past six months, its share price has underperformed the S&P500 Index by -24.51%.
As of the last closing price of $6.19, shares in Lifevantage were trading +1.84% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Lifevantage PE Ratio?
The Lifevantage PE ratio based on its reported earnings over the past 12 months is 9.12. The shares last closed at $6.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Lifevantage?
Lifevantage's management team is headed by:
- Garry Mauro - NEC
- Steven Fife - PRE
- Carl Aure - CFO
- Matthew Cooley - COO
- Justin Rose - CMO
- Alissa Neufeld - GCN
- Michael Beindorff - IND
- Erin Brockovich - IND
- Raymond Greer - IND
- Darwin Lewis - IND